<DOC>
	<DOC>NCT00525447</DOC>
	<brief_summary>This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.</brief_summary>
	<brief_title>Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosis of multiple myeloma. Received at least one prior systemic therapy other than singleagent corticosteroids. Measurable disease of monoclonal protein greater than or equal to 0.5 gram/dL in plasma or 0.5 gram/24 hr urine collection, or greater than 10 mg/dL free light chain (FLC) in serum as determined by serum FLC assay and provided the serum FLC ratio is abnormal. Received an allogenic stem cell transplant. Previous intolerance of lenalidomide or dexamethasone. Primary invasive malignancy (other than multiple myeloma) within the last 3 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Antigens, CD40</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Hemostatic Disorders</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Antibody-Dependent Cell Cytotoxicity</keyword>
</DOC>